RheumaGen, Inc.
Biotechnology company · Denver, Colorado, United States
RheumaGen, Inc. is a biotechnology company headquartered in Denver, Colorado, United States. Its earliest recorded incorporation is in 2022. It has received 1 US government small-business research award (SBIR/STTR) from health agencies, $306,827 in total, most recently in 2025. It has reported private securities offerings to the US SEC, most recently $700,000 sold in a notice filed in 2024.
RheumaGen at a glance
What does RheumaGen do?
US government research funding
1 SBIR/STTR small-business research award from US health agencies, $306,827 in total (2025). NIH funding came from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Private fundraising reported to the SEC
4 Form D notices; the most recent reported $700,000 sold (2024).
Frequently asked questions about RheumaGen
Where is RheumaGen headquartered?
RheumaGen, Inc. is headquartered in Denver, Colorado, United States.
What does RheumaGen do?
RheumaGen, Inc. is a biotechnology company.
When was RheumaGen founded?
The earliest incorporation on record for RheumaGen, Inc. is in 2022, according to public company registers.
Similar companies
- Vitro Biopharma, Inc.Denver, Colorado, United States
- BioCollective, LLCDenver, Colorado, United States
- BioMedInnovations LLCDenver, North Carolina, United States
- Cerecin Inc.Denver, Colorado, United States
- Cascade Biocatalysts, Inc.Denver, Colorado, United States
- Op-T-Mune, IncDenver, Colorado, United States
- Rock Immune, Inc.Denver, Colorado, United States
- Ursa AnalyticsDenver, Colorado, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesLast updated 2026-09-23. Data licences